Catheter Ablation Registry

March 15, 2016 updated by: National Heart, Lung, and Blood Institute (NHLBI)
To assess factors associated with safety and efficacy of catheter ablation using direct current or radiofrequency energy for the management of patients with drug and/or pacemaker resistant cardiac arrhythmias.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

BACKGROUND:

Cardiac tachyarrhythmias that are refractory to either conventional or experimental antiarrhythmic therapy, antitachycardia pacemakers, or both, may result in serious symptoms or death. Catheter ablation has been developed as a nonpharmacologic, closed-chest alternative for the management of these patients. The technique was first applied to man in 1981 and reported by both Scheinman et al and Gallagher et al in 1982. Hartzler reported the first catheter ablation procedure for the treatment of ventricular tachycardia in 1983. In that same year, Weber reported the first use of catheter ablation of an accessory atrioventricular pathway. The standard method of energy delivery for closed-chest catheter ablation attempts involved direct current delivered using a defibrillator, but beginning in 1985, radiofrequency energy was employed in man. This promised to revolutionize the field of catheter ablation, because it offered the hope of more precise destruction of tissue, avoided the need for general anesthesia and significantly lowered complication rates, since it did not involve the levels of energy used in direct current attempts.

The Catheter Ablation Registry (CAR) evolved from a pilot study, the Percutaneous Cardiac Mapping and Ablation Registry (PCMAR) formed in 1983. There were scientific limitations in this voluntary registry. Further prospective studies were needed to better define this procedure, and a multicenter international prospective cohort study was designed to allow a rapid assessment of ablation's dangers and potential usefulness. Results from the study were used to guide physicians as to which patients would and would not benefit from these new procedures.

DESIGN NARRATIVE:

Data were collected prospectively from sixteen clinical centers in the United States and Europe on attempted catheter ablation of the atrioventricular junction, accessory atrioventricular pathways and ventricular tachycardia. Each of the three ablation techniques was studied as a separate subset and the two methods of energy delivery, direct current or radiofrequency energy, were compared within each subset. A standardized protocol was used for direct current ablation and the results of a variety of protocols for the other two procedures and for radiofrequency energy were observed. Patients were evaluated quarterly in the first post-procedure year, and biannually for the subsequent duration of the study. Statistical analyses were performed to determine the distribution of specific patient characteristics such as age, sex, clinical status, underlying heart disease, and a variety of procedural categories including energy level, mapping data, and catheter position. A determination was made of the frequency of successful outcomes including cessation of arrhythmias, production of third degree atrioventricular block, and disappearance of symptoms and of adverse effects, including procedure-related complications and death.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

Study Type

Observational

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

No older than 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

No eligibility criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 1986

Study Completion (Actual)

August 1, 1991

Study Registration Dates

First Submitted

May 25, 2000

First Submitted That Met QC Criteria

May 25, 2000

First Posted (Estimate)

May 26, 2000

Study Record Updates

Last Update Posted (Estimate)

March 16, 2016

Last Update Submitted That Met QC Criteria

March 15, 2016

Last Verified

September 1, 2002

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1074
  • R01HL035077 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Diseases

Clinical Trials on Catheter ablation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe